STOCK TITAN

Delcath Systems to Participate at the BTIG MedTech, Digital Health, Life Sciences & Diagnostic Tools Conference on February 14 to 16

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

Delcath Systems, Inc. (NASDAQ: DCTH) is set to participate in the BTIG MedTech, Digital Health, Life Sciences, & Diagnostics Tools Conference from February 14 to 16, 2023, in Snowbird, Utah. CEO Gerard Michel will hold one-on-one meetings during the event. The company specializes in treating primary and metastatic liver cancers, utilizing its percutaneous hepatic perfusion (PHP) system to deliver high-dose chemotherapy while minimizing side effects. In the U.S., the PHP system is under development as HEPZATO™ KIT for metastatic ocular melanoma, while in Europe, it's marketed as CHEMOSAT.

Loading...
Loading translation...
Argus Session date unavailable
-1.60% session move Open Argus
Details

News Market Reaction – DCTH

The recorded move for DCTH in the trading session of this news was -1.60%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

NEW YORK, Jan. 30, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the BTIG MedTech, Digital Health, Life Sciences, & Diagnostics Tools Conference in Snowbird, Utah on February 14 to 16.

Delcath CEO, Gerard Michel will be conducting one-on-one meetings. To request a one-on-one meeting please contact your BTIG representative with interest.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO™ KIT (melphalan hydrochloride for injection/Hepatic Delivery System), or HEPZATO, for the treatment of patients with unresectable hepatic-dominant metastatic ocular melanoma (mOM), also known as metastatic uveal melanoma (mUM) and is considered a combination drug and device product regulated as a drug by the United States Food and Drug Administration (FDA).

In Europe, the PHP system is now regulated as a Class lll medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.

Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/delcath-systems-to-participate-at-the-btig-medtech-digital-health-life-sciences--diagnostic-tools-conference-on-february-14-to-16-301733027.html

SOURCE Delcath Systems, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Delcath Systems, Inc. participating in on February 14 to 16, 2023?

Delcath Systems, Inc. will participate in the BTIG MedTech, Digital Health, Life Sciences, & Diagnostics Tools Conference.

Who is the CEO of Delcath Systems, Inc.?

The CEO of Delcath Systems, Inc. is Gerard Michel.

What is the purpose of Delcath's percutaneous hepatic perfusion system?

The PHP system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and related side effects.

What is HEPZATO™ KIT developed for?

HEPZATO™ KIT is developed for treating patients with unresectable hepatic-dominant metastatic ocular melanoma.

What is CHEMOSAT and where is it approved?

CHEMOSAT is the name for Delcath's PHP system in Europe, approved as a Class III medical device for treating various liver cancers.

Keep reading